Article
Increasing rates of erm (B) and erm (N) in human Campylobacter coli and Campylobacter jejuni erythromycin-resistant isolates between 2018 and 2023 in France
31 Dec 2024
Abstract excerpt
ABSTRACT Macrolides are the first-line compounds used for the treatment of campylobacteriosis. Macrolide resistance remains low in France, with mutations in 23S rDNA being the main associated resistance mechanism. However, two erythromycin methyltransferases have also been identified : erm (B), which is mainly described in animal reservoirs, and erm (N), which is strictly described in humans. In France, between...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
